Heron Therapeutics CFO acquires 3,874 shares

The chief financial officer’s restricted stock units vest in 16 equal quarterly installments, beginning one quarter after the January 19, 2024 grant date.

Rhea-AI Filing Summary

Heron Therapeutics, Inc. reported that its EVP, Chief Financial Officer, Ira Duarte, exercised 3,874 restricted stock units into 3,874 common shares on October 19, 2026. On that date, 1,102 common shares were delivered or withheld for payment of exercise price or tax liability, at a reported $0.36 per share. The derivative transaction reported 19,372 restricted stock units following the exercise. The units vest in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date. No Rule 10b5-1 plan is reported.

Insider Trade Summary

3,874 shares exercised/converted

Exercise 3 txns

Insider Duarte Ira

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F2	3,874	$0.00	$0.00
Exercise	Common Stock F1	3,874	--	--
Exercise Price or Tax Liability	Common Stock	1,102	$0.36	$396.72

Holdings After Transaction: Restricted Stock Units — 19,372 contracts (Direct); Common Stock — 284,671 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. F2. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Key Figures

Restricted stock units exercised: 3,874 restricted stock units Common shares acquired: 3,874 shares Shares delivered or withheld for payment of exercise price or tax liability: 1,102 shares +2 more

5 metrics

Restricted stock units exercised 3,874 restricted stock units October 19, 2026

Common shares acquired 3,874 shares October 19, 2026

Shares delivered or withheld for payment of exercise price or tax liability 1,102 shares Reported at $0.36 per share on October 19, 2026

Reported restricted stock units following derivative transaction 19,372 restricted stock units Following the October 19, 2026 transaction

Vesting installments 16 equal quarterly installments Beginning one quarter after the January 19, 2024 grant date

Key Terms

restricted stock unit, contingent right, quarterly installments, exercise price or tax liability

4 terms

restricted stock unit financial

"Each restricted stock unit represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents a contingent right to receive one share of common stock"

quarterly installments financial

"vest in 16 equal quarterly installments"

exercise price or tax liability financial

"payment of exercise price or tax liability"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What HRTX shares did CFO Ira Duarte acquire and deliver on October 19, 2026?

Ira Duarte acquired 3,874 common shares through the reported restricted stock unit exercise, and 1,102 common shares were delivered or withheld for payment of exercise price or tax liability. The reported price for those shares was $0.36 per share; no Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 12:04 PM EDT Accepted by SEC EDGAR 10/21/2026 - 12:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duarte Ira

(Last) (First) (Middle)

25 FENTON MAIN STREET

SUITE 300

(Street)

CARY NORTH CAROLINA 27511

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/19/2026		M		3,874	A	(1)	285,773	D
Common Stock	10/19/2026		F		1,102	D	$0.36	284,671	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	10/19/2026		M			3,874	(2)	(2)	Common Stock	3,874	$0	19,372	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

	/s/Kathryn Lester Attorney-in-fact for Ira Duarte	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)